Compare CRNX & MEOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | MEOH |
|---|---|---|
| Founded | 2008 | 1968 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.8B |
| IPO Year | 2018 | 1995 |
| Metric | CRNX | MEOH |
|---|---|---|
| Price | $39.51 | $59.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $76.63 | $55.89 |
| AVG Volume (30 Days) | 1.1M | ★ 2.2M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | $25.43 |
| Revenue Next Year | $184.67 | N/A |
| P/E Ratio | ★ N/A | $16.44 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $26.47 |
| 52 Week High | $57.99 | $66.75 |
| Indicator | CRNX | MEOH |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 54.13 |
| Support Level | $39.35 | $33.22 |
| Resistance Level | $45.32 | $66.75 |
| Average True Range (ATR) | 1.61 | 4.14 |
| MACD | 0.85 | -0.28 |
| Stochastic Oscillator | 87.76 | 56.86 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Methanex Corp manufactures and sells methanol. Its customers use methanol as a feedstock to produce end-products including adhesives, foams, solvents, and windshield washer fluids. The firm also sells its products to the oil refining industry, where the methanol is blended with gasoline to produce a high-octane fuel or blended as a component of biodiesel. It distributes its products through an extensive supply chain that includes the operation of port terminals, tankers, barges, rail cars, trucks, and pipelines. The company generates the majority of its revenue from Europe.